Bookmark and Share
BioAssay: AID 488768

qHTS Assay to Find Inhibitors of T. brucei Phosphofructokinase: Summary

Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the millions of people worldwide who are infected by these parasites and endangering hundreds of millions more. Many of the disorders caused by trypanosomatids are fatal if left untreated, but most currently used drugs are inefficient and toxic. ..more
_
   
AID: 488768
Data Source: NCGC (PFK003s)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2010-10-11
Target
Related Experiments
Show more
AIDNameTypeComment
485367qHTS Assay to Find Inhibitors of T. brucei phosphofructokinaseConfirmatorydepositor-specified cross reference: PFK qHTS screen
485368qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinaseConfirmatorydepositor-specified cross reference: PFK validation assay
492961qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validationConfirmatorydepositor-specified cross reference
504636Tb PFK orthogonal confirmatory assay using ATP depletion (Kinase-Glo Plus) as an alternative measure of Tb PFK activity: Hit ValidationConfirmatorydepositor-specified cross reference
504637Inhibitors of T. brucei phosphofructokinase: Hit ValidationConfirmatorydepositor-specified cross reference
540360Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: probe SARConfirmatorydepositor-specified cross reference
588323Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Cytotoxictity in MRC5Confirmatorydepositor-specified cross reference
588324Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Counter Screen against T cruzi PFKConfirmatorydepositor-specified cross reference
588325Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Cytotoxictity in KB-3-1Confirmatorydepositor-specified cross reference
588329Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: ATP-depletion AssayConfirmatorydepositor-specified cross reference
588330Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: High ATPConfirmatorydepositor-specified cross reference
588331Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: High F6PConfirmatorydepositor-specified cross reference
588332Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: Counter Screen against Bacillus PFKConfirmatorydepositor-specified cross reference
588333Confirmatory Assay to Find Inhibitors of T. brucei phosphofructokinase: T. brucei in vitro Parasite AssayOtherdepositor-specified cross reference
624130qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Aqueous Kinetic SolubilityOtherdepositor-specified cross reference
624131qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Mouse Liver Microsome StabilityOtherdepositor-specified cross reference
624142qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Human Liver Microsome StabilityOtherdepositor-specified cross reference
624143qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Mouse Plasma Stability ProfilingOtherdepositor-specified cross reference
624144qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: Human Plasma Stability ProfilingOtherdepositor-specified cross reference
Description:
NIH Molecular Libraries Probe Production Network [MLPCN]
NIH Chemical Genomics Center [NCGC]

Grant: 1 R03 MH092153-01
PI Name: Malcolm Walkinshaw, University of Edinburgh

NCGC Assay Overview:

Various species of the protozoan family Trypanosomatidae are responsible for a range of serious human diseases in tropical and subtropical areas of the world. The subspecies Trypanosoma brucei is one of three known to cause sleeping sickness in sub-Saharan Africa, significantly contributing to the millions of people worldwide who are infected by these parasites and endangering hundreds of millions more. Many of the disorders caused by trypanosomatids are fatal if left untreated, but most currently used drugs are inefficient and toxic.
Of many possible drug targets in trypanosomatid parasites, the carbohydrate metabolism pathway is seen as potentially one of the most selective, as T. brucei, when in the bloodstream of its mammalian host, is entirely dependent on the conversion of the blood sugar glucose into pyruvate for its ATP supply [1]. Oxidative metabolism involving the mitochondrial tricarboxylic acid cycle and oxidative phosphorylation are repressed in these parasites, and recent RNA interference (RNAi) experiments have shown that even partial depletion of certain individual glycolytic enzymes can lead to the death of cultured parasites [2]. One such glycolytic enzyme, phosphofructokinase (PFK), catalyzes the formation of fructose-1,6-bisphosphate (F1,6BP) and ADP from fructose-6-phosphate (F6P) and ATP, and in many metabolic circumstances makes an important contribution to the control of flux through the glycolytic pathway. As a specific glycolytic target, PFK is particularly attractive as it catalyzes the first irreversible step in glycolysis, and structural and kinetic studies have shown very substantial and essential differences from corresponding host enzymes [3], allowing for the discovery of parasite-selective inhibitors.
The goal of this screen is to find small-molecule inhibitors of T. brucei PFK using a biochemical assay that measures PFK activity as a function of ADP production. A luminescence-based assay for T. brucei PFK activity has been developed which uses luciferase to detect production of ADP. Traditional luciferase-based nucleotide detection reagents rely on ATP production as a direct substrate for the luciferase reaction; however, PFK catalyzes the transfer of a phosphate from ATP to F6P, resulting in the net depletion of ATP. To directly measure the ADP product of the PFK reaction, we used the ADP-Glo detection kit (Promega), which utilizes two separate reactions to 1) deplete all remaining uncatalyzed ATP and 2) convert all remaining ADP to ATP, which is then detected through a traditional luciferase-coupled reaction. Compounds were screened as a concentration-titration series that ranged from 57 uM to 0.7 nM.
Protocol
Please refer to AIDs 485367 and 485368 for assay details.
Comment
This in an ongoing project, we will make the update accordingly once a probe is identified.
Categorized Comment - additional comments and annotations
From MLP Probe Report:
Probe count: 1
MLP Probe ML# for probe 1: ML251
PubChem Substance ID (SID) for probe 1: 124391163
PubChem Compound ID (CID) for probe 1: 53255421
Probe type for probe 1: Inhibitor
IC50/EC50 (nM) for probe 1: 370
Target for probe 1: Tb PFK (gi: 72386991)
Disease relevance for probe 1: Human African Trypanosomiasis
Anti-target for probe 1: Cytotoxicity (KB-3-1 Cells)
Fold selectivity for probe 1: >100
NCBI Book chapter link for probe 1: http://www.ncbi.nlm.nih.gov/books/NBK154498/ (ID: 3050958)
Grant number for probe 1: MH092153-01
NCBI Book chapter title for probe 1: Identification of Selective Inhibitors of Phosphofructokinase as Lead Compounds Against Trypanosomiasis
Additional Information
Grant Number: 1 R03 MH092153-01

PageFrom: